Free Trial
NASDAQ:AIMT

Aimmune Therapeutics (AIMT) Stock Price, News & Analysis

→ At first glance, this chart looks like nonsense… (From The TradingPub) (Ad)
Free AIMT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$34.49
▼
$34.49
50-Day Range
$34.30
▼
$34.59
52-Week Range
$10.09
▼
$37.00
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
AIMT stock logo

About Aimmune Therapeutics Stock (NASDAQ:AIMT)

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

AIMT Stock News Headlines

June 30, 2022 | finance.yahoo.com
Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
November 12, 2021 | financialpost.com
Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting
April 23, 2024 | True Market Insiders (Ad)
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
October 26, 2021 | finance.yahoo.com
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
August 4, 2021 | ca.finance.yahoo.com
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
See More Headlines
Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/30/2020
Today
4/23/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AIMT
CUSIP
N/A
CIK
1631650
Web
www.aimmune.com
Phone
650-614-5220
Fax
N/A
Employees
228
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-248,500,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-164.99%
Return on Assets
-89.50%

Debt

Debt-to-Equity Ratio
0.73
Current Ratio
7.53
Quick Ratio
7.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.66 per share
Price / Book
20.78

Miscellaneous

Outstanding Shares
65,450,000
Free Float
N/A
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.76
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Jayson Donald Alexander Dallas (Age 51)
    Pres, CEO & Director
  • Mr. Eric H. Bjerkholt (Age 59)
    Chief Financial Officer
  • Mr. Douglas T. Sheehy (Age 52)
    Gen. Counsel & Sec.
  • Dr. Stephen George Dilly (Age 59)
    Special Advisor
  • Dr. Daniel C. Adelman (Age 62)
    Chief Medical Officer

Key Competitors

View All Competitors

AIMT Stock Analysis - Frequently Asked Questions

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.06).

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Block (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU).

When did Aimmune Therapeutics IPO?

Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

This page (NASDAQ:AIMT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
SHOCKING Crypto Leak…
Crypto 101 Media
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
American Alternative
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Exposed: 10 CENT Crypto to Explode April 20th?
True Market Insiders